Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical analysis of continuing crizotinib treatment beyond disease progression in ALK-positive non-small-cell lung cancer patients

Date

08 Oct 2016

Session

Poster Display

Presenters

Liu Hongmei

Citation

Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383

Authors

L. Hongmei1, M. Huang2, Y. Xu2, X. Zhou3, J. Li4, J. Wang2, F. Peng2, Y. Gong2, Z. Ding2, J. Zhu2, P. Yu4, L. Li2, M. Hou2, L. Ren2, Y. Wang2, Y. Lu2

Author affiliations

  • 1 Department Of Thoracic Oncology, Cancer Center, West China Hospital, Huaxi, Sichuan University, 610041 - Chengdu/CN
  • 2 Department Of Thoracic Oncology, Cancer Center, State Key Laboratory Of Biotherapy, West China Hospital, Huaxi, Sichuan University, Chengdu/CN
  • 3 Department Of Thoracic Oncology, Cancer Center, State Key Laboratory Of Biotherapy, West China Hospital, Huaxi, Sichuan University, 610041 - Chengdu/CN
  • 4 Lung Cancer Medical Oncology, Sichuan Cancer Hospital, Chengdu/CN
More

Resources

Background

Continuing the treatment of tyrosine kinase inhibitors (TKIs) after disease progression (PD) in EGFR-mutation NSCLC was reported promising in several studies, but rare research presented continued ALK-TKIs beyond PD in NSCLC. Thus, we retrospectively analyzed the continuation of crizotinib treatment beyond PD in ALK-positive patients.

Methods

The progression free survival (PFS, time from first crizotinib dose to first RECIST-defined PD), PFS2 (time from continuing crizotinib treatment beyond PD to drug withdrawal or death), overall survival (OS, time from first crizotinib dose to death), objective response rate (ORR) and disease control rate (DCR) were analyzed in this study. Patterns of PD were identified by patients underwent rapid radiographic/clinical disease progression or died within 3 months after PD.

Results

Of 108 patients screened, 53 patients got PD at the cutoff time. Median follow-up was 12.3 months. After PD, 23 patients discontinued crizotinib treatment and 30 patients continued. Baseline characteristics showed that continued ones had a better ECOG performance status than discontinued ones (P = 0.006). Patterns of PD was significantly different in two groups (P 

Conclusions

ALK-positive NSCLC may get clinical benefits from the continuation of crizotinib beyond PD, especially in those patients with brain or bone metastases.

Clinical trial identification

-

Legal entity responsible for the study

Department of Thoracic Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Medical School, Sichuan University

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings